glutathione and cancer Human cancer-associated fibroblasts enhance levels antagonize drug-induced prostate cell death Targeting the Vulnerability of Glutathione

Central and peripheral metabolic defects contribute to the pathogenesis of Alzheimers disease: targeting mitochondria for diagnosis and prevention

In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8 or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24 or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors

ergothioneine stays stable in tissue for months

Typical cycles run 412 weeks, depending on goals

Rat blood serum samples were pre- equilibrated at 37C and then (50g) of each drug solution was added to 90 of rat serum in 1 .5mL Eppendorf tube maintained at 37C